Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
City of Hope Medical Center
Kura Oncology, Inc.
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
Hoosier Cancer Research Network
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.
ETOP IBCSG Partners Foundation
Hoffmann-La Roche
Bristol-Myers Squibb
Mirati Therapeutics Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bristol-Myers Squibb
Incyte Corporation
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Sanofi
Verastem, Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
M.D. Anderson Cancer Center
Zai Lab (Hong Kong), Ltd.